Aerie Pharmaceuticals Inc. (AERI)

[crudeoil24]

Aerie Pharma Says New Glaucoma Drug Superior to its Components
46 minutes ago - DJNF


By Joshua Jamerson



Aerie Pharmaceuticals Inc. (AERI) said Wednesday that its once-daily glaucoma treatment proved in a mid-stage trial to be statistically superior to each of its two components.

Shares rose 28% in recent premarket trading.

The company said the drug, Roclatan, is a combination of its Rhopressa drug and latanoprost, a leading glaucoma drug. The drug maker also said it seeks to move the drug to Phase 3 registration trials.

"With this success we believe we have an approvable product, and Phase 3 preparatory activities for Roclatan are commencing immediately," said Aerie Chief Executive Vicente Anido.

If approved for commercialization, Aerie believes Roclatan would be the only glaucoma product that treats the full spectrum of known mechanisms that cause increased pressure inside the eye.



Write to Joshua Jamerson at [e-mail]